SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-285213
Filing Date
2020-11-04
Accepted
2020-11-04 09:00:29
Documents
1
Period of Report
2020-10-29
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K d202550d8k.htm 8-K 19204
  Complete submission text file 0001193125-20-285213.txt   20254
Mailing Address 7318 MORTON STREET DALLAS TX 75209
Business Address 7318 MORTON STREET DALLAS TX 75209 212.551.8702
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

IRS No.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39536 | Film No.: 201285356
SIC: 2836 Biological Products, (No Diagnostic Substances)